Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2025

Feb 10, 2025

30291_dirs_2025-02-10_bdff674c-1579-463d-ad9e-a514a0105a41.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2025-02-06

Reporting Person: Viehbacher Christopher (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-02-07 Common Stock M 9008 Acquired 16008 Direct
2025-02-07 Common Stock F 3201 $141.35 Disposed 12807 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-02-06 Restricted Stock Unit $0 A 46360 Acquired 2028-02-06 Common Stock (46360) Direct
2025-02-07 Restricted Stock Unit $0 M 9008 Disposed 2027-02-07 Common Stock (9008) Direct

Footnotes

F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.

F2: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.